NO2024005I1 - Combination of trifluridine and tipiracil or a salt thereof with bevacizumab - Google Patents

Combination of trifluridine and tipiracil or a salt thereof with bevacizumab

Info

Publication number: NO2024005I1
Authority: NO; Norway
Prior art keywords: tipiracil; trifluridine; bevacizumab; salt; combination
Prior art date: 2013-09-06

Application number

NO2024005C

Other languages

English (en)

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-06

Filing date

2024-01-25

Publication date

2024-01-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2024005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2024-01-25 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2024-01-25 Publication of NO2024005I1 publication Critical patent/NO2024005I1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Endocrinology (AREA)

NO2024005C 2013-09-06 2024-01-25 Combination of trifluridine and tipiracil or a salt thereof with bevacizumab NO2024005I1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2013184684		2013-09-06

Publications (1)

Publication Number	Publication Date
NO2024005I1 true NO2024005I1 (no)	2024-01-25

Family

ID=52628493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2024005C NO2024005I1 (no)	2013-09-06	2024-01-25	Combination of trifluridine and tipiracil or a salt thereof with bevacizumab

Country Status (24)

Country	Link
US (1)	US9943537B2 (no)
EP (2)	EP4201424A1 (no)
JP (2)	JP6425653B2 (no)
KR (1)	KR101993963B1 (no)
AU (1)	AU2014316030C1 (no)
CY (2)	CY1126037T1 (no)
DK (1)	DK3042669T3 (no)
ES (1)	ES2946472T3 (no)
FI (2)	FI3042669T3 (no)
FR (1)	FR24C1005I1 (no)
HR (1)	HRP20230523T1 (no)
HU (2)	HUE062034T2 (no)
LT (1)	LT3042669T (no)
NO (1)	NO2024005I1 (no)
PL (1)	PL3042669T3 (no)
PT (1)	PT3042669T (no)
RS (1)	RS64243B1 (no)
RU (1)	RU2682161C2 (no)
SI (1)	SI3042669T1 (no)
SM (1)	SMT202300167T1 (no)
TW (1)	TWI641385B (no)
UA (1)	UA121538C2 (no)
WO (1)	WO2015034032A1 (no)
ZA (1)	ZA201602258B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20230523T1 (hr)	2013-09-06	2023-08-04	Taiho Pharmaceutical Co., Ltd.	Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
MA43590A (fr)	2016-01-08	2018-11-14	Taiho Pharmaceutical Co Ltd	Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
US20190160054A1 (en) *	2016-04-13	2019-05-30	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
US20200148757A1 (en) *	2017-06-30	2020-05-14	Korea Advanced Institute Of Science And Technology	Conjugate of vegf-grab protein and drug, and use thereof
KR20220154986A (ko)	2021-05-14	2022-11-22	윤상은	휴대용 마스크끈 절단기
AR127893A1 (es) *	2021-12-10	2024-03-06	Servier Lab	Terapia del cáncer dirigida a egfr
IL313434A (en)	2022-01-21	2024-08-01	Chugai Pharmaceutical Co Ltd	Medicine for treating or preventing cancer
WO2023204259A1 (ja)	2022-04-20	2023-10-26	中外製薬株式会社	がんの治療又は予防用医薬
WO2024177036A1 (ja) *	2023-02-20	2024-08-29	大鵬薬品工業株式会社	Ｆｔｄ・ｔｐｉ配合剤、ｐｄ－１経路アンタゴニスト、及びｖｅｇｆ経路アンタゴニストの併用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT763529E (pt)	1995-03-29	2003-12-31	Taiho Pharmaceutical Co Ltd	Derivados de uracilo potenciador de efeito antitumor e agente antitumor que os contem
US7312243B1 (en) *	2003-08-29	2007-12-25	Jay Pravda	Materials and methods for treatment of gastrointestinal disorders
US7799783B2 (en) *	2005-01-26	2010-09-21	Taiho Pharmaceutical Co., Ltd.	Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP5576591B2 (ja)	2005-01-26	2014-08-20	大鵬薬品工業株式会社	α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
PT2979700T (pt) *	2013-03-27	2018-12-27	Taiho Pharmaceutical Co Ltd	Agente antitumoral que inclui cloridrato de irinotecano hidratado em dose baixa
KR101847252B1 (ko) *	2013-03-27	2018-04-09	다이호야쿠힌고교 가부시키가이샤	이리노테칸염산염 수화물을 함유하는 항종양제
HRP20230523T1 (hr)	2013-09-06	2023-08-04	Taiho Pharmaceutical Co., Ltd.	Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta

2014
- 2014-09-05 HR HRP20230523TT patent/HRP20230523T1/hr unknown
- 2014-09-05 AU AU2014316030A patent/AU2014316030C1/en active Active
- 2014-09-05 TW TW103130882A patent/TWI641385B/zh active
- 2014-09-05 RU RU2016112421A patent/RU2682161C2/ru active
- 2014-09-05 EP EP23154967.6A patent/EP4201424A1/en active Pending
- 2014-09-05 EP EP14842538.2A patent/EP3042669B1/en active Active
- 2014-09-05 PT PT148425382T patent/PT3042669T/pt unknown
- 2014-09-05 RS RS20230421A patent/RS64243B1/sr unknown
- 2014-09-05 FI FIEP14842538.2T patent/FI3042669T3/fi active
- 2014-09-05 US US14/916,878 patent/US9943537B2/en active Active
- 2014-09-05 SI SI201432026T patent/SI3042669T1/sl unknown
- 2014-09-05 ES ES14842538T patent/ES2946472T3/es active Active
- 2014-09-05 KR KR1020167005952A patent/KR101993963B1/ko active IP Right Grant
- 2014-09-05 LT LTEPPCT/JP2014/073436T patent/LT3042669T/lt unknown
- 2014-09-05 SM SM20230167T patent/SMT202300167T1/it unknown
- 2014-09-05 JP JP2015535524A patent/JP6425653B2/ja active Active
- 2014-09-05 WO PCT/JP2014/073436 patent/WO2015034032A1/ja active Application Filing
- 2014-09-05 HU HUE14842538A patent/HUE062034T2/hu unknown
- 2014-09-05 PL PL14842538.2T patent/PL3042669T3/pl unknown
- 2014-09-05 DK DK14842538.2T patent/DK3042669T3/da active
- 2014-09-05 UA UAA201603578A patent/UA121538C2/uk unknown
2016
- 2016-04-05 ZA ZA2016/02258A patent/ZA201602258B/en unknown
2018
- 2018-01-15 JP JP2018004516A patent/JP6557744B2/ja active Active
2023
- 2023-06-07 CY CY20231100271T patent/CY1126037T1/el unknown
2024
- 2024-01-24 FR FR24C1005C patent/FR24C1005I1/fr active Active
- 2024-01-24 CY CY2024001C patent/CY2024001I2/el unknown
- 2024-01-24 HU HUS2400001C patent/HUS2400001I1/hu unknown
- 2024-01-25 FI FIC20240002C patent/FIC20240002I1/fi unknown
- 2024-01-25 NO NO2024005C patent/NO2024005I1/no unknown

Also Published As

Publication number	Publication date
JPWO2015034032A1 (ja)	2017-03-02
RU2016112421A (ru)	2017-10-11
RU2682161C2 (ru)	2019-03-15
US9943537B2 (en)	2018-04-17
AU2014316030C1 (en)	2024-08-15
FI3042669T3 (fi)	2023-05-25
LT3042669T (lt)	2023-06-26
EP3042669B1 (en)	2023-03-08
PT3042669T (pt)	2023-06-15
KR101993963B1 (ko)	2019-06-27
US20160193241A1 (en)	2016-07-07
EP3042669A4 (en)	2017-04-12
CY2024001I1 (el)	2024-09-20
ES2946472T3 (es)	2023-07-19
JP2018076369A (ja)	2018-05-17
HUS2400001I1 (hu)	2024-02-28
TW201536319A (zh)	2015-10-01
HRP20230523T1 (hr)	2023-08-04
EP3042669A1 (en)	2016-07-13
SMT202300167T1 (it)	2023-07-20
RU2016112421A3 (no)	2018-06-20
AU2014316030A1 (en)	2016-04-28
CY1126037T1 (el)	2023-11-15
UA121538C2 (uk)	2020-06-25
RS64243B1 (sr)	2023-06-30
AU2014316030B2 (en)	2019-02-28
KR20160050026A (ko)	2016-05-10
CY2024001I2 (el)	2024-09-20
JP6425653B2 (ja)	2018-11-21
FR24C1005I1 (fr)	2024-04-19
HUE062034T2 (hu)	2023-09-28
SI3042669T1 (sl)	2023-07-31
FIC20240002I1 (fi)	2024-01-25
DK3042669T3 (da)	2023-06-12
PL3042669T3 (pl)	2023-06-26
TWI641385B (zh)	2018-11-21
JP6557744B2 (ja)	2019-08-07
ZA201602258B (en)	2017-09-27
EP4201424A1 (en)	2023-06-28
WO2015034032A1 (ja)	2015-03-12

Publication	Publication Date	Title
NO2024005I1 (no)	2024-01-25	Combination of trifluridine and tipiracil or a salt thereof with bevacizumab
IL270218B (en)	2021-01-31	Anti-activin a antibodies and uses thereof
NL301154I2 (nl)	2022-07-18	Mometason of een zout daarvan en olopatadine of een zout daarvan
HK1217719A1 (zh)	2017-01-20	人類區變體及其用途
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
PT3052485T (pt)	2021-10-22	Compostos heterocíclicos e suas utilizações
BR302014001153S1 (pt)	2015-05-05	Configuração aplicada em fechamento
EP3527146C0 (en)	2023-12-27	SURGICAL CLOSURE
FI20135956A (fi)	2015-02-21	Kiinnitin
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
PL3030519T3 (pl)	2022-05-23	Trójpierścieniowe związki benzoksaborolu i ich zastosowania
EP2982505A4 (en)	2016-06-08	FEATURE FILM
ES1087479Y (es)	2013-11-15	Objeto de adorno
EP2969728C0 (en)	2024-12-25	HANDLE-POWERED VELOCIPEDE
DK2969131T3 (da)	2020-03-23	Cos- og cs2-reduktionsfremgangsmåde
DK2968528T3 (da)	2022-03-28	Immunmodulation
BR112015023621A8 (pt)	2018-01-23	derivados de meropenem e suas utilizações
FR3007291B1 (fr)	2015-07-17	Composition cicatrisante et utlisation
FI20145444A (fi)	2014-11-17	Parvekerunko ja parveke
ES1078825Y (es)	2013-06-10	Elemento de cerramiento
TH148825B (th)	2016-04-18	สารประกอบเตตระโซลิโนนและการใช้ของสิ่งนั้น
FI10349U1 (fi)	2014-01-15	Tulvahälytyskokoonpano
TH1401006791B (th)	2016-06-03	ฟิล์มโพลีเอสเตอร์และกรรมวิธีการผลิตนั้น
TH1401005596A (th)	2016-09-28	โพลิเอสเตอร์และวัตถุที่ผลิตขึ้นจากโพลิเอสเตอร์ดังกล่าว